Raloxifene, a SERM targets PD-L1: an in-silico study.

ABSTRACT:

Objectives

Immunotherapeutic interventions in cancer have been considerably successful and widely accepted for cancer treatment, but are costly and cannot be afforded by all patients. Because of the high cost, the pharmaceutical research groups across the world are sufficiently motivated to discover or design small molecule inhibitors to treat cancer through inhibition of the immune checkpoint proteins previously targeted with monoclonal antibodies. The presented study was designed with an aim to establish raloxifene, a selective estrogen receptor modulator (SERM) as a potential ligand of the immune checkpoint protein Programmed death ligand-1 (PD-L1).

Methods

In the presented study, the in-silico approach was used for identifying a lead molecule against PD-L1. The hi

SUBMITTER: Chopra C 

PROVIDER: S-EPMC10492081 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature